
    
      This is an open-label, single-center pilot study to investigate the pharmacodynamics,
      pharmacokinetics (PK), safety, and activity of pembrolizumab administered intra-lymphatically
      using the DoseConnect in participants with relapsed or refractory cutaneous T-cell lymphoma
      (CTCL).

      All participants will receive the study intervention, pembrolizumab administered
      intralymphatically using the Sofusa DoseConnect device.
    
  